Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | ACP3 | P15309 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25111092 | 0.84 | HDAC4 (0.38) | PNMTDAOTSHRCTSS | |
| SCHEMBL11824304 | 0.83 | PNMT (0.45) | PNMTDAOIDO1TDO2HTR2A | |
| SCHEMBL7952419 | 0.82 | PNMT (0.47) | PNMTDAOIDO1TDO2HTR2A | |
| SCHEMBL28061635 | 0.81 | TACR1 (0.37) | IDO1TDO2CES2MAPTCTSS | |
| SCHEMBL28284728 | 0.81 | TACR1 (0.37) | IDO1TDO2CES2MAPTCTSS | |
| SCHEMBL5188795 | 0.80 | PNMT (0.49) | PNMTDAOIDO1TDO2HTR2A | |
| SCHEMBL255035 | 0.79 | PNMT (0.55) | PNMTDAOIDO1TDO2HTR2A | |
| SCHEMBL2601113 | 0.79 | DAO (0.59) | PNMTDAOIDO1TDO2HTR2A | |
| SCHEMBL10959497 | 0.79 | TRPA1 (0.52) | PNMTDAOIDO1TDO2HTR2A | |
| SCHEMBL15391010 | 0.79 | PNMT (0.47) | PNMTDAOIDO1TDO2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709708-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ANGELINI PHARMA S.P.A. (IT) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233603-A1 | NOVEL CARBOXAMIDE DERIVATIVES | ICAGEN, LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-101495458-B | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER IP GMBH | 2014-01-29 | — | — | CN | disclosed |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| EP-2027096-B1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer Pharma AG (DE) | 2012-05-23 | — | — | EP | disclosed |
| EP-2027096-B1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer Pharma AG (DE) | 2012-05-23 | — | — | EP | disclosed |
| CN-102369190-A | Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency | BAYER SCHERING PHARMA AG | 2012-03-07 | — | — | CN | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| CN-101495458-A | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER HEALTHCARE AG (DE) | 2009-07-29 | — | — | CN | disclosed |
| EP-2027096-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer HealthCare AG (DE) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
| US-4656233-A | \"Living\" polymers and chain transfer-regulated polymerization process | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0186330-A1 | \"Living\" polymers and chain transfer-regulated polymerization process | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | PNMT 935/4885DAO 1612/4885IDO1 2882/4885 |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | PNMT 1101/4885DAO 567/4885IDO1 1570/4885 |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | AVPR2, AVPR1A, AVPR1B | PNMT 1101/4885DAO 567/4885IDO1 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.